# Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Study · id `cardio:ct-nct02617290` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02617290](<https://clinicaltrials.gov/study/NCT02617290>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02617290

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1900 participants.

## Technical summary

Registry record NCT02617290. Randomized; no masking; primary purpose treatment. Start 2017-01-09 (actual); primary completion 2020-05-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1900 participants (enrolled count; ClinicalTrials.gov record NCT02617290, source copy `cardio:ctgov-nct02617290-2020-10-14`, retrieved 2026-10-26)
- Started: 2017-01-09 (actual) (ClinicalTrials.gov record NCT02617290, source copy `cardio:ctgov-nct02617290-2020-10-14`, retrieved 2026-10-26)
- Primary completion: 2020-05-29 (actual) (ClinicalTrials.gov record NCT02617290, source copy `cardio:ctgov-nct02617290-2020-10-14`, retrieved 2026-10-26)
- Completion: 2020-09-15 (actual) (ClinicalTrials.gov record NCT02617290, source copy `cardio:ctgov-nct02617290-2020-10-14`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT02617290, source copy `cardio:ctgov-nct02617290-2020-10-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02617290-2020-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
- Acronym: ALPHEUS
- Condition: Coronary Artery Disease
- Condition: Myocardial Ischemia
- Condition: Myocardial Infarction
- Condition: Stent Thrombosis
- Condition: Cardiovascular Diseases
- Intervention (Drug): Ticagrelor
- Intervention (Drug): Clopidogrel
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Action Research Group
- Collaborator class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Action Research Group (`cardio:org-action-research-group`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial (`cardio:pubmed-33202219`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impacts of stent characteristics on periprocedural ischemic events in elective PCI: the ALPHEUS-stents study (`cardio:pubmed-41999954`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Definition and Prediction of Periprocedural Myocardial Infarction in Elective Percutaneous Coronary Intervention: The ALPHEUS-MI Study (`cardio:pubmed-41763360`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b007b51e7847c802460dced78a3508717cc3ffff68b86ea50a4f95ec82303898
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
